Indaptus Therapeutics, Inc.

Indaptus Therapeutics, Inc.verified

INDP

Price:

$0.9092

Market Cap:

$10.92M

Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.[Read more]

Industry

Biotechnology

IPO Date

2015-08-04

Stock Exchange

NASDAQ

Ticker

INDP

The ROE as of December 2024 (TTM) for Indaptus Therapeutics, Inc. (INDP) is -177.27%

According to Indaptus Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -177.27%. This represents a change of 273.10% compared to the average of -47.51% of the last 4 quarters.

Indaptus Therapeutics, Inc. (INDP) Historical ROE (quarterly & annually)

How has INDP ROE performed in the past?

The mean historical ROE of Indaptus Therapeutics, Inc. over the last ten years is 61.44%. The current -177.27% ROE has changed -388.55% with respect to the historical average. Over the past ten years (40 quarters), INDP's ROE was at its highest in in the December 2020 quarter at 324.03%. The ROE was at its lowest in in the September 2019 quarter at -116.53%.

Quarterly (TTM)
Annual

Average

61.44%

Median

-57.31%

Minimum

-412.65%

Maximum

1.50%

Indaptus Therapeutics, Inc. (INDP) ROE by Quarter and Year

Discovering the peaks and valleys of Indaptus Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 407.44%

Maximum Annual ROE = 1.50%

Minimum Annual Increase = -463.86%

Minimum Annual ROE = -412.65%

Quarterly (TTM)
Annual
YearROEChange
2023-127.71%129.03%
2022-55.76%160.20%
2021-21.43%-101.43%
20201.50%-463.86%
2019-412.65%407.44%
2018-81.32%65.41%
2017-49.16%-16.46%
2016-58.85%192.18%
2015-20.14%-66.48%
2014-60.09%9.63%

Indaptus Therapeutics, Inc. (INDP) Average ROE

How has INDP ROE performed in the past?

The current ROE of Indaptus Therapeutics, Inc. (INDP) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

-68.30%

5-year avg

176.78%

10-year avg

61.44%

Indaptus Therapeutics, Inc. (INDP) ROE vs. Peers

How is INDP’s ROE compared to its peers?

Indaptus Therapeutics, Inc.’s ROE is greater than Rezolute, Inc. (-69.83%), greater than Tempest Therapeutics, Inc. (-187.44%), less than Comera Life Sciences Holdings, Inc. (67.46%), greater than Forte Biosciences, Inc. (-151.43%), greater than ABVC BioPharma, Inc. (-98.40%), greater than Pasithea Therapeutics Corp. (-81.66%), less than Better Therapeutics, Inc. (129.80%), greater than Nutriband Inc. (-62.97%), greater than Quoin Pharmaceuticals, Ltd. (-126.19%), greater than Longeveron Inc. (-142.15%), greater than RenovoRx, Inc. (-242.57%), greater than Virax Biolabs Group Limited (-115.10%), greater than Blue Water Vaccines, Inc. (-126.11%), greater than Revelation Biosciences, Inc. (-311.33%), greater than Hillstream BioPharma, Inc. (-172.28%), less than Kiora Pharmaceuticals, Inc. (21.31%), greater than Anebulo Pharmaceuticals, Inc. (-184.40%), less than ZIVO Bioscience, Inc. (618.61%), greater than Metacrine, Inc. (-83.52%), greater than Assembly Biosciences, Inc. (-121.46%),

Build a custom stock screener for Indaptus Therapeutics, Inc. (INDP) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Indaptus Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Indaptus Therapeutics, Inc. (INDP) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Indaptus Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the ROE?

How can you use the ROE?

What is Indaptus Therapeutics, Inc.'s ROE?

How is the ROE calculated for Indaptus Therapeutics, Inc. (INDP)?

What is the highest ROE for Indaptus Therapeutics, Inc. (INDP)?

What is the 3-year average ROE for Indaptus Therapeutics, Inc. (INDP)?

What is the 5-year average ROE for Indaptus Therapeutics, Inc. (INDP)?

How does the current ROE for Indaptus Therapeutics, Inc. (INDP) compare to its historical average?